🔎 Trials Near Me

Akèy › Lukemi lenfositè kwonik › Alabama

Etid klinik pou Lukemi lenfositè kwonik nan Alabama

7 etid pou Lukemi lenfositè kwonik ap chèche patisipan nan sit nan Alabama.

Vil nan Alabama

Tèks ofisyèl etid la (Anglè)

Testing the Addition of Anti-Cancer Drug Sonrotoclax, to the Standard Treatment Zanubrutinib, for Previously Untreated CLL/SLL

  • University of Alabama at Birmingham Cancer Center, Birmingham
Ap rekriteFaz 3
Laj 65 ak plis · Tout sèks · Mizajou Oct 2, 2026 · NCT07321652

A Dose-Escalation and Expansion Study of Tacabrutideg (BGB-16673) in Participants With B-Cell Malignancies

  • University of Alabama At Birmingham Hospital, Birmingham
Ap rekriteFaz 1/2
Laj 18 ak plis · Tout sèks · Mizajou Sep 28, 2026 · NCT05006716

A Study to Evaluate the Safety and Efficacy of Tacabrutideg (BGB-16673) Compared to Pirtobrutinib in Adults With Relapsed/Refractory Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma

  • University of Alabama At Birmingham Hospital, Birmingham
Ap rekriteFaz 3
Laj 18 ak plis · Tout sèks · Mizajou Sep 28, 2026 · NCT06973187

A Study of Pirtobrutinib (LY3527727) in Participants With Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma

  • Mitchell Cancer Institute, Mobile
Ap rekriteFaz 4
Laj 18 ak plis · Tout sèks · Mizajou Sep 22, 2026 · NCT07218341

Study of SLS009 (Formerly GFH009) a Potent Highly Selective CDK9 Inhibitor in Patients With Hematologic Malignancies and High-Risk Newly Diagnosed AML

  • O'Neal Comprehensive Cancer Center, University of Alabama, Birmingham
Ap rekriteFaz 1/2
Laj 12 ak plis · Tout sèks · Mizajou Sep 3, 2026 · NCT04588922

HPC Offered for PRESERVE Expansion

  • University of Alabama, Birmingham, Birmingham
Ap rekriteEtid obsèvasyon
Laj 12 a 80 · Tout sèks · Mizajou Aug 28, 2025 · NCT07145411

Sous ClinicalTrials.gov, done yo ranmase Oct 5, 2026. Chak etid gen kritè li pou li menm; ekip etid la deside ki moun ki ka patisipe.